Reproductive Medicine Center, Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University Shanghai 200080, China.
National Institute for Data Science in Health and Medicine, School of Medicine, Xiamen University, Xiamen, China.
Reprod Biomed Online. 2022 Dec;45(6):1182-1187. doi: 10.1016/j.rbmo.2022.06.026. Epub 2022 Jul 4.
What is the effect of letrozole use in patients undergoing frozen embryo transfer (FET) with normal ovulation? Although the number of FETs is increasing, an optimal protocol for FET (particularly vitrified-warmed embryo transfer) is yet to be determined. The aim of this study was to evaluate letrozole use on patients with normal menstrual cycles compared with hormone replacement therapy (HRT) cycles and natural cycles.
The study involved 2849 patients. Patients were divided into three groups: HRT cycle (n = 2115), letrozole cycle (n = 532) and natural cycle (n = 202). Inverse probability of treatment weighting aimed to equate each group according to measured baseline covariates to achieve a comparison with reduced selection bias and live birth rate as main pregnancy outcome was analysed.
In the crude analysis, the letrozole group had a higher live birth rate compared with the HRT cycle (OR 1.18, 95% CI 1.06 to 1.33) and natural cycle (OR 1.24, 95% CI 1.11 to 1.41); after adjusting for confounding factors, live birth rate was consistently higher in the letrozole group. Moreover, the biochemical pregnancy, clinical pregnancy, ongoing pregnancy and full-term delivery rates were higher in the letrozole group.
For infertile women with normal menstrual cycle undergoing FET, mildly stimulated cycles with letrozole present a relatively large advantage compared with HRT cycle and natural cycle, with higher live birth pregnancy, indicating that letrozole administration could improve pregnancy outcomes in this population.
在排卵正常的患者中进行冻融胚胎移植(FET)时,来曲唑的使用效果如何?尽管 FET 的数量正在增加,但最佳的 FET 方案(特别是玻璃化冷冻胚胎移植)仍有待确定。本研究旨在评估与激素替代疗法(HRT)周期和自然周期相比,来曲唑用于正常月经周期患者的效果。
该研究涉及 2849 名患者。患者被分为三组:HRT 周期组(n=2115)、来曲唑周期组(n=532)和自然周期组(n=202)。采用逆概率治疗加权法(inverse probability of treatment weighting),根据测量的基线协变量对每组进行均衡处理,以实现比较,并降低选择偏倚,主要妊娠结局为活产率。
在粗分析中,与 HRT 周期(OR 1.18,95%CI 1.06 至 1.33)和自然周期(OR 1.24,95%CI 1.11 至 1.41)相比,来曲唑组的活产率更高;在调整混杂因素后,来曲唑组的活产率仍持续较高。此外,来曲唑组的生化妊娠、临床妊娠、持续妊娠和足月分娩率较高。
对于排卵正常的接受 FET 的不孕妇女,与 HRT 周期和自然周期相比,使用来曲唑的轻度刺激周期具有相对较大的优势,活产妊娠率更高,表明来曲唑给药可以改善该人群的妊娠结局。